AllianceRx Walgreens Prime study demonstrates increased adherence and improvement in symptoms for psoriasis patients switching to interleukin-17 inhibitors

ORLANDO, Fla. – Sept. 11, 2019 – AllianceRx Walgreens Prime announced results from a new study analyzing data from patients prescribed interleukin-17 (IL-17) inhibitors for psoriasis. Patients reported improvements in psoriatic symptoms and demonstrated increased medication adherence after switching to one of the three IL-17 medications included in the study...